<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0402256809
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOBAT 500 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BATTERJEE PHARMACETICAL FACTORY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LEVOBAT<br />500 Tablets contain a medicine called levofloxacin. This belongs to a group of medicines<br />called antibiotics. Levofloxacin is a &lsquo;quinolone&rsquo; antibiotic. It works by killing the bacteria that cause<br />infections in your body.<br />LEVOBAT<br />500 tablets can be used to treat bacterial infections in the:<br /> Sinuses.<br /> Lungs, in people with long-term breathing problems or pneumonia.<br /> Urinary tract, including your kidneys or bladder.<br /> Prostate gland, where you have a long lasting bacterial infection.<br /> Skin and underneath the skin, including muscles. This is sometimes called soft tissue.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take LEVOBAT 500 Tablets if you:<br /> You are allergic to levofloxacin, any other quinolone antibiotic such as moxifloxacin, ciprofloxacin or ofloxacin or any of the other ingredients of LEVOBAT 500 Tablets (listed in Section 6 below). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.<br /> You have ever had epilepsy.<br /> You have ever had a problem with your tendons such as tendonitis that was related to treatment with a &lsquo;quinolone antibiotic&#39;. A tendon is the cord that joins your muscle to your skeleton.<br /> You are a child or a growing teenager.</p><p> You are pregnant, might become pregnant or think you may be pregnant.<br /> You are breast-feeding.<br />Do not take this medicine if any of<br />the above apply to you. If you are not sure, talk to your doctor or<br />pharmacist before taking LEVOBAT 500 Tablets.</p><p>Take special care with LEVOBAT 500 Tablets<br />Tell your doctor if:<br /> You are 65 years of age or older.<br /> You are using corticosteroids, sometimes called steroids (see &ldquo;Taking other medicines&rdquo; below).<br /> You have ever had a seizure.<br /> You have had damage to your brain due to a stroke or other brain injury.<br /> You have kidney problems.<br /> You have something known as &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. You are more likely to have serious problems with your blood when taking this medicine.<br /> You have ever had mental health problems.<br /> You have ever had heart or liver problems.<br /> You are diabetic.<br />If you are not sure if any of the above applies to you, talk<br />to your doctor or pharmacist before taking<br />LEVOBAT 500 Tablets</p><p>Taking other medicines<br />There are some medicines that may interact with LEVOBAT 500 Tablets Tablets. Make sure your doctor knows if you are taking any of the following medicines:<br /> Corticosteroids, sometimes called steroids &ndash; used for inflammation. You may be more likely to have inflammation and/or breakage of your tendons.<br /> Warfarin - used to thin the blood. You may be more likely to have a bleed. Your doctor may need to take regular blood tests to check how well your blood can clot.<br /> Theophylline - used for breathing problems. You are more likely to have a seizure if taken with LEVOBAT 500 Tablets.<br /> Non-steroidal anti-inflammatory drugs (NSAIDS) - used for pain and inflammation such as aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a seizure if taken with LEVOBAT 500 Tablets.<br /> Cyclosporine - used after organ transplants. You may be more likely to get the side effects of Cyclosporine.<br /> Medicines known to affect the way your heart beats. This includes medicines used for abnormal heart rhythm (anti-arrhythmic such as quinidine and amiodarone), for depression (tricyclic antidepressants such as amitriptyline and imipramine) and for bacterial infections (&lsquo;macrolide&rsquo; antibiotics such as erythromycin, azithromycin and Clarithromycin).</p><p> Probenecid - used for gout, and cimetidine - used for ulcers and heartburn. Special care should be taken when taking either of these medicines with LEVOBAT 500 Tablets Tablets. If you have kidney problems, your doctor may want to give you a lower dose.<br /> Taking of iron tablets (for anemia), magnesium or aluminum containing antacids (for acid or<br />heartburn) or sulcralfate (for stomach ulcers) at the same time with LEVOBAT 500 Tablets may<br />affect the way LEVOBAT 500 Tablets work<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>Urine tests for opiates<br />Urine tests may show &lsquo;false-positive&rsquo; results for strong painkillers called &lsquo;opiates&rsquo; in people taking<br />LEVOBAT 500 Tablets. If your doctor is due to take a urine test, tell them you are taking LEVOBAT 500 Tablets.</p><p>Pregnancy and breast-feeding<br />Do not take this medicine if:<br /> You are pregnant or might become pregnant.<br /> You are breast-feeding.<br />Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or breast-feeding.</p><p>Driving and using machines<br />You may get side effects after taking this medicine, including feeling dizzy, sleepy, a spinning feeling (vertigo) or changes to your eyesight. Some of these side effects can affect you being able to<br />concentrate and your reaction speed. If this happens, do not drive or carry out any work that requires a high level of attention.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take your medicine exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure.<br />Swallow the tablet whole by mouth with a glass of water. The tablets may be taken during meals or at<br />any time between meals.<br />Protect your skin from sunlight<br />Keep out of direct sunlight while taking this medicine. This is because your skin will become much more sensitive to the sun and may burn, tingle or severely blister if you do not take the following precautions:<br /> Make sure you use high factor sun cream.<br /> Always wear a hat and clothes which cover your arms and legs.</p><p> Avoid sun beds.</p><p>If you are already taking iron tablets, antacids or sulcralfate<br /> Do not take these medicines at the same time as LEVOBAT 500 Tablets . Take your dose at least 2<br />hours before or after LEVOBAT 500 Tablets</p><p>How much to take<br /> Your doctor will decide on how many LEVOBAT 500 Tablets you should take.<br /> The dose will depend on the type of infection you have and where the infection is in your body.<br /> The length of your treatment will depend on how serious your infection is.<br /> If you feel the effect of your medicine is too weak or strong, do not change the dose yourself, but ask your doctor.<br />Adults and the elderly<br /> Sinuses : one tablet of LEVOBAT 500 mg , once each day</p><p> Lungs, in people with long term breathing problems : half tablet or one tablet of LEVOBAT 500<br />mg, once each day<br /> Pneumonia : one tablet of LEVOBAT 500 mg, once or twice each day<br /> Urinary tract, including your kidneys or bladder : half tablet of LEVOBAT 500 mg , once each day<br /> Prostate gland : one tablet of LEVOBAT 500 mg, once each day<br /> Skin and underneath the skin, including muscles : half tablet or one tablet of LEVOBAT 500 mg,<br />once or twice each day</p><p>Adults with kidney problems<br />Your doctor may need to give you a lower dose.</p><p>Children and Teenagers<br />This medicine must not be given to children or teenagers.<br />If you take more LEVOBAT 500 Tablets than you should<br />If you accidentally take more tablets than you should, tell a doctor or get other medical<br />advice straight<br />away. Take the medicine pack with you. This is so the doctor knows what you have taken. The<br />following effects may happen: convulsive fits (seizures), feeling confused, dizzy, less conscious and<br />heart problems leading to uneven heart beats as well as feeling sick (nausea).</p><p>If you forget to take LEVOBAT 500 Tablets</p><p>If you forgot to take a dose, take it as soon as you remember unless it is nearly time for your next dose.<br />Do not double up the next dose to make up for the missed dose.<br />If you stop taking LEVOBAT 500 Tablets<br />Do not stop taking LEVOBAT 500 Tablets just because you feel better. It is important that you complete the course of tablets that your doctor has prescribed for you. If you stop taking the tablets too soon, the infection may return, your condition may get worse or the bacteria may become resistant to the medicine.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines,<br />LEVOBAT 500 Tablets can cau se side effects, although not everybody gets them.<br />These effects are normally mild or moderate and often disappear after a short time.<br />Stop taking LEVOBAT 500 Tablets and see a doctor or go to a hospital straight away if you notice the following side effect:</p><p>Very rare (affects less than 1 person in 10,000)</p><p> You have an allergic reaction. The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat, or tongue</p><p> Increased sensitivity of your skin to sun and ultraviolet light.</p><p> Lowering of your blood sugar levels (hypoglycemia). This is important for people that have diabetes</p><p> Problems with your hearing or eyesight or changes in the way things taste and smell</p><p> Seeing or hearing things that are not there (hallucinations), change in your opinion and thoughts (psychotic reactions) with a chance of having suicidal thoughts or actions</p><p> Loss of circulation (anaphylactic like shock)  Muscle weakness. This is important in people with myasthenia gravis (a rare disease of the nervous system)</p><p> Inflammation of the liver, changes in the way your kidney works and occasional kidney failure which may be due to an allergic kidney reaction called interstitial nephritis</p><p> Fever, sore throat and a general feeling of being unwell that does not go away. This may be due to a lowering in the number of white blood cells</p><p> Fever and allergic lung reactions</p><p> Burning, tingling, pain or numbness. These may be signs of something called &lsquo;neuropathy&rsquo;</p><p>&nbsp;</p><p>Stop taking LEVOBAT 500 tablets and see a doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:</p><p>Rare (affects less than 1 person in 1000)</p><p> Watery diarrhea which may have blood in it, possibly with stomach cramps and a high temperature. These could be signs of a severe bowel problem</p><p> Pain and inflammation in your tendons. The Achilles tendon is affected most often and in some cases, the tendon could break</p><p> Fits (convulsions)</p><p> Tingly feeling in your hands and feet (par aesthesia) or trembling</p><p> Feeling stressed (anxiety), depressed, mental problems, feeling restless (agitation) or feeling confused  Unusual fast beating of your heart or low blood pressure</p><p> Joint pain or muscle pain</p><p> Bruising and bleeding easily due to a lowering in the number of blood platelets</p><p> Low number of white blood cells (called neutropenia)</p><p> Difficulty breathing or wheezing (bronchospasm)</p><p> Shortness of breath (dyspnea)  Severe itching or hives (called urticaria)</p><p>&nbsp;</p><p>Other:</p><p> Severe skin rashes which may include blistering or peeling of the skin around your lips, eyes, mouth, nose and genitals</p><p> Loss of appetite, skin and eyes becoming yellow in colour, dark-coloured urine, itching, or tender stomach (abdomen). These may be signs of liver problems Tell your doctor if any of the following side effects gets serious or lasts longer than a few days:</p><p>&nbsp;</p><p>Common (affects less than 1 person in 10)</p><p> Feeling sick (nausea) and diarrhoea</p><p> Increase in the level of some liver enzymes in your blood Uncommon (affects less than 1 person in 100)</p><p> Itching and skin rash</p><p> Loss of appetite, stomach upset or indigestion (dyspepsia), being sick (vomiting) or pain in your stomach area, feeling bloated (flatulence) or constipation</p><p> Headache, feeling dizzy, a spinning feeling (vertigo), feeling sleepy, sleeping problems or feeling nervous</p><p> Blood tests may show unusual results due to liver or kidney problems  Changes in the number of white blood cells shown up in the results of some blood tests</p><p> General weakness</p><p> Changes in the number of other bacteria or fungi may increase, which may need to be treated Other side effects include:</p><p> Lowering in red blood cells (anemia). This can make the skin pale or yellow due to damage of the red blood cells and lowering in the number of all types of blood cells</p><p> Exaggerated immune response (hypersensitivity)</p><p> Sweating too much (hyperhidrosis)</p><p> Pain, including pain in the back, chest and extremities</p><p> Problems moving and walking</p><p> Attacks of porphyria in people who already have porphyria (a very rare metabolic disease)</p><p> Inflammation of your tubes that carry blood around your body (vessels) due to an allergic reaction If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Don&rsquo;t Store LEVOBAT 500 Tablets above 30&deg;C.<br />Do not use LEVOBAT 500 Tablets after the expiry date (EXP) which is stated on the carton and foil.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is levofloxacin. Each tablet of<br />LEVOBAT 500 mg tablets c ontains 500 mg of<br />levofloxacin as levofloxacin hemihydrate<br />The other ingredients are:<br />Tablet core:<br />Pregelatinized Starch, crospovidone, microcrystalline cellulose, lactose anhydrous and magnesium stearate.<br />Tablet coat:<br />Hydroxyl propyl methyl cellulose and opadry red OY-S-35002.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LEVOBAT
500 tablets are reddish brown oblong shaped tablets , coded with BP 15 and scored from the
same side
The medicine is available in a c arton box containing one blister PVC /PVDC Aluminium containin g 5
coated tablets and a pamphlet

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BATTERJEE PHARMA<br />Street No.: 401, Road No.: 403,<br />Industrial Area-Phase-IV,<br />P.O. Box: 10667, Jeddah-21443,<br />Kingdom of Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوى أقراص ليفوبات 500 على مادة الفعالة تدعى ليفوفلوكساسين ينتمى لمجموعة من الأدوية تسمى مضادات حيوية<br />الليفوفلوكساسين هو مضاد حيوى من فئة الكينولون يعمل عن طريق قتل البكتريا التى تسبب العدوى فى جسمك.<br />تستخدم أقراص ليفوبات 500 لعلاج الإصابات البكتيرية فى :<br />- الجيوب الأنفية.<br />- الرئتين لدى الأشخاص المصابين بمشاكل مزمنة فى التنفس أو الألتهاب الرئوى.<br />- المسالك البولية بمافيها الكلى أو المثانة.<br />- الغدة البروستاتية عندما تكون لديك عدوى بكتيرية طويلة الأمد.<br />- الجلد وما تحت الجلد بما فى ذلك العضلات بما يسمى عادة بالنسيج اللين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب ألا تتناول أقراص ليفوبات 500 في حال :<br /> إذا كنت تعاني من حساسية ضد الليفوفلوكساسين أو مضاد حيوى أخر من فئة الكينولون مثل موكسيفلوكساسين أو<br />سيبروفلوكساسين أو أوفلوكساسين أو أى من المكونات الأخرى لأقراص ليفوبات 500)مذكوره فى قسم 6 أدناه(.<br />تتضمن أعراض الحساسية : طفح, مشاكل فى البلع أو التنفس, تورم الشفتين أو الوجه أو الحلق أو اللسان.<br /> إذا أصبت يوما بالصرع.<br /> إذا عانيت يوما من مشكلة فى الأوتار مثل إلتهاب الوتر الناتج عن العلاج بمضاد حيوى من فئة الكينولون. الوتر هو الحبل الذى<br />يصل مابين عضلك وهيكلك العظمى.<br /> إذا كنت طفلا أو مراهقا فى طور النمو.<br /> إذا كنتى حاملا أو قد تصبحين حاملا أو تعتقدين أنك حاملا.<br /> إذا كنتى مرضعة.</p><p>لا تأخذ هذا الدواء إذا كنت تعانى من إحدى الحالات المذكورة أعلاه. إذا لم تكن متأكدا استشر الطبيب أو الصيدلى قبل تناول أقراص<br />. ليفوبات 500<br />إتخذ عناية خاصة مع أقراص ليفوبات 500<br />أخبر طبيبك إذا:<br /> كنت فى ال 65 من العمر أو أكثر.<br /> كنت تتناول ستيرويدات قشرية وتسمى أحيانا ستيرويدات ) راجع فقرة تناول أدوية أخرى أدناه (.<br /> أصبت يوما بالصرع.<br /> تعرض دماغك للضرر بسبب سكتة دماغية أو إصابة أخرى فى الدماغ.<br /> تعانى من مشاكل كلوية.<br /> تعانى من نقص فى هيدروجين جلوكوز 6 فوسفات, حيث تكون معرضا لمشاكل أكثر خطورة فى الدم عند تناول هذا الدواء. - -<br /> عانيت يوما من مشاكل فى الصحة العقلية.<br /> عانيت يوما من مشاكل فى القلب أو الكبد.<br /> كنت مصابا بداء السكرى.<br />. إذا كنت غير متأكد مما إذا كانت تنطبق عليك إحدى الحالات أعلاه, إستشر الطبيب أو الصيدلى قبل تناول أقراص ليفوبات 500</p><p>تناول أدوية أخرى<br />بعض الأدوية ممكن أن تؤثر على عمل أقراص ليفوبات 500 لذلك أخبر طبيبك إذا كنت تتناول أى من الأدوية التالية :<br /> الستيرويدات القشرية التى تسمى أحيانا بالستيرويدات وتستعمل للإلتهابات. فقد يزيد خطر تعرضك لإلتهاب الأوتار أو لتمزقها.<br /> الوارفارين المستعمل لترقيق الدم. فقد يزيد خطر تعرضك لنزيف. قد يحتاج طبيبك إجراء فحوصات دم لك بإنتظام للتحقق من<br />قدرة دمك على التخثر.<br /> . الثيوفيلين المستعمل لمشاكل التنفس. فقد يزيد تعرضك لنوبة صرع إذا تناولته مع أقراص ليفوبات 500<br /> مضادات الإلتهاب غير الستيرويدية التى تستعمل لتسكين الألم والإلتهابات مثل الأسبرين والإيبوبروفين والفينبوفين و<br />. الكيتوبروفين والإندوميثاسين. فقد يزيد خطر تعرضك لنوبة صرع إذا ما تناولتها مع أقراص ليفوبات 500<br /> السيكلوسبورين المستعمل بعد زرع الأعضاء فقد يزيد خطر تعرضك للأثار الجانبية للسيكلوسبورين.<br /> الأدوية التى يعرف عنها أنها تؤثر على دقات القلب وتتضمن الأدوية المستعملة لعلاج ضربات القلب الغير طبيعية )مضادات<br />اللانظمية مثل الكينيدين والأميودارون( وللإكتئاب )مضاد الإكتئاب الثلاثية الدورة مثل الأميتربتيلين والإيميبرامين( ولحالات<br />الإصابة البكتيرية )المضادات الحيوية من فئة الماكروليد مثل الإيريثرومايسين والأزيثرومايسين والكلاريثرومايسين(.<br /> بروبينسيد المستعمل للنقرس و سيميتيدين المستعمل للقرحة وحرقة المعدة. يجب إعتماد عناية خاصة عند تناول أحد هذين<br />الدوائين مع ليفوبات 500. إذا كنت تعانى من مشاكل كلوية قد يصف لك طبيبك جرعة أدنى.</p><p>تناول أقراص الحديد )لفقر الدم( أو المجنيزيوم أو مضادات الحموضة التى تحتوى على الألومنيوم )للحموضة أو حرقة المعدة(<br />. أو سكرالفات )لقرحة المعدة( فى الوقت ذاته مع أقراص ليفوبات 500 يمكن أن تؤثر على طريقة عمل أقراص ليفوبات 500</p><p>فحوصات البول للمواد الإفيونية<br />قد تظهر فحوصات البول نتائج إيجابية كاذبة تدل على وجود مستحضرات أفيونية لدى المرضى الذين يتناولون أقراص ليفوبات<br />. 500. فى حال طلب منك الطبيب إجراء فحص بول أعلمه أنك تتناول أقراص ليفوبات 500</p><p>&nbsp;</p><p>الحمل والإرضاع<br />لا تتناولى هذا الدواء إذا:<br /> كنتى حاملا أو قد تصبحين حاملا.<br /> كنتى مرضعة.<br />إستشيرى طبيبك أو الصيدلى قبل تناول أى دواء إذا كنتى حاملا أو مرضعة.</p><p>القيادة وأستعمال الآلات<br />قد تتعرض لتأثيرات جانبية بعد تناول هذا الدواء بما فى ذلك الشعور بالدوخة والنعاس والدوار أو بتغييرات فى النظر. ويمكن أن تؤثر<br />بعض هذه التأثيرات الجانبية على قدرتك على التركيز وعلى سرعة ردة الفعل لديك. فى حال حصول هذا, لا تقد سيارة ولا تقم بأى<br />عمل يتطلب مستوى عاليا من الإنتباه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائما أقراص ليفوبات 500 حسب وصفة الطبيب تماما. عليك التأكد من الطبيب أو الصيدلى إذا لم تكن واثقا.<br />إبلع القرص كامل عبر الفم مع كوب من الماء. يمكن تناول الأقراص مع الطعام أو فى أى وقت كان بين الوجبات.<br />إحمى بشرتك من أشعة الشمس<br />لا تتعرض لأشعة الشمس المباشرة خلال فترة تناولك هذا الدواء. لأن بشرتك ستصبح أكثر حساسية بكثير تجاه الشمس وقد تحترق أو<br />تشعر بوخز خفيف أو تمتلئ بشرتك بالبثور إذا لم تتخذ الإحتياطات التالية:<br />- إحرص على إستعمال مرهم وقاية قوى من أشعة الشمس.<br />- إرتد دائما قبعة وإرتد ثيابا تغطى ذراعيك وساقيك.<br />- تفاد حمامات الشمس.<br />إذا كنت تتناول أقراص حديد أو مضادات حموضة أو سكرالفات<br />لا تتناول هذه الأدوية بالتزامن مع أقراص ليفوبات 500. خذ جرعتك من هذه الأدوية قبل أو بعد ساعتين على الأقل من تناول أقراص<br />ليفوبات 500 أقراص.<br />مقدار الجرعة<br />- سيقرر طبيبك عدد أقراص ليفوبات 500 التى عليك تناولها.<br />- تتوقف الجرعة على نوع العدوى ومكان تلك العدوى فى جسمك.<br />- تتوقف مدة العلاج على خطورة العدوى التى تعانى منها.<br />- إذا شعرت أن مفعول دوائك ضعيف جدا أو قوى جدا لا تغير الجرعة من تلقاء نفسك بل إستشر الطبيب.<br />البالغون والمسنون<br />الجيوب الأنفية: قرص ليفوبات 500 مرة واحده فى اليوم.<br />الرئتان لدى المرضى الذين يعانون من مشاكل تنفسية طويلة الأمد: نصف قرص أو قرص ليفوبات 500 مرة واحدة فى اليوم.<br />الألتهاب الرئوى: قرص ليفوبات 500 مرة واحدة أو مرتان فى اليوم.<br />المسالك البولية بما فى ذلك الكليتان أو المثانة: نصف قرص ليفوبات 500 فى اليوم.<br />الغدة البروستاتية: قرص ليفوبات 500 مرة واحدة فى اليوم.<br />الجلد وماتحت الجلد بما فى ذلك العضلات: نصف قرص أو قرص ليفوبات 500 مرة أو مرتان فى اليوم.<br />البالغون الذين يعانون مشاكل كلوية<br />قد يضطر طبيبك إلى إعطائك جرعة أدنى.<br />الأطفال والمراهقون<br />يمنع إعطاء هذا الدواء للأطفال أو المراهقين.<br />إذا أخذت إقراص ليفوبات 500 أكثر من التى عليك أخذها<br />إذا أخذت عن غير قصد أقراص ليفوبات 500 أكثر من التى يجب عليك أخذها، أعلم الطبيب أو أحصل على رأى طبى أخر فورا. خذ<br />علبة الدواء معك كى يعرف الطبيب ماذا أخذت. قد تتعرض للتأثيرات التالية: نوبات صرعية، تشوش ذهنى، دوار، فقد للوعى<br />ومشاكل قلبية تؤدى إلى عدم إنتظام دقات القلب وإلى الشعور بالغثيان.<br />إذا نسيت تناول أقراص ليفوبات 500<br />إذا نسيت تناول جرعة خذها حالما تتذكر إلا إذا حان الأوان لجرعتك التالية. لا تتناول جرعة مضاعفة للتعويض عن الجرعة التى<br />نسيتها.<br />إذا توقفت عن تناول أقراص ليفوبات 500<br />لاتتوقف عن تناول اقراص ليفوبات 500 لأنك تشعر بتحسن. من المهم أن تأخذ كل الأقراص التى وصفها لك طبيبك. إذا توقفت عن<br />تناول أقراصك قبل إنتهاء العلاج ، قد تعاودك حالة العدوى أو قد تسوء حالتك أو قد تصبح البكتيريا مقاومة للدواء.<br />إذا كان لديك أسئلة أخرى عن إستعمال هذا الدواء، إطرحها على الطبيب أو الصيدلى.<br />&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>٤.التاثيرات الجانبية المحتملة<br />مثل جميع الأدوية يمكن أن يسبب ليفوبات 500 تأثيرات جانبية لا تصيب المرضى كلهم. عادة ما تكون هذه الآثار خفيفة إلى معتدلة<br />وغالبا ماتختفى بعد فترة قصيرة.<br />توقف عن تناول أقراص ليفوبات 500 واذهب إلى الطبيب أو إلى المستشفى على الفور إذا لاحظت التأثير الجانبى التالى:<br />) نادرة جدا )تصيب اقل من شخص واحد من أصل 10000<br />- تصاب بحساسية قد تتضمن الأعراض: طفح , مشاكل فى البلع أو التنفس, تورم الشفتين أو الوجه أو الحلق أو اللسان.<br />- شعور بالحرق أو الوخز أو الألم أو الخدر. قد تكون هذه اعراض مرض يسمى الاعتلال العصبى.<br />- زيادة الحساسية تجاه الشمس والأشعة فوق البنفسجية.<br />- إنخفاض مستوى سكر الدم )نقص سكر الدم(. هذا مهم للأشخاص المصابين بداء السكرى.<br />- مشاكل فى السمع أو البصر أو تغييرات فى حاستى الذوق والشم.<br />- رؤية أو سماع أشياء غير موجودة )هلاوس(، تغيير فى رأيك و أفكارك )رد فعل ذهنية( مع خطر أن تراودك أفكار أو أفعال<br />إنتحارية.<br />- فقدان الدوران )صدمة تشبه الصدمة الأستهدافية(.<br />- ضعف عضلى، هذا مهم لدى الأشخاص المصابين بالوهن العضلى اليوبيل )مرض نادر يصيب الجهاز العصبى(.<br />- إلتهاب الكبد، تغييرات فى طريقة عمل الكلى وقصور كلوى عرضى قد يكون نتيجة لإرتكاس كلوى تحسسى يسمى إلتهاب الكلية<br />الخلالى.<br />- حمى، إلتهاب الحلق وشعور عام بالتوعك لايزول. قد يكون هذا نتيجة إنخفاض كريات الدم البيضاء.</p><p>حمى وإرتكاسات رئوية تحسسية.<br />) نادرة )تصيب اقل من شخص واحد من أصل 1000<br />- إسهال حاد يمكن ان يحتوى على دم وقد يترافق مع مغص معوى وحرارة مرتفعة. قد تكون هذه اعراض مشكلة فى الأمعاء.<br />- ألم وإلتهاب فى الأوتار، غالبا مايصاب وتر العرقوب ويمكن أن يتمزق فى بعض الحالات.<br />- نوبات )تشنجات(.<br />- شعور بالوخز فى اليدين والقدمين )تنمل( أو رجفان.<br />- الشعور بالضغط )قلق( أو بالإكتئاب، مشاكل عقلية، الشعور بعدم الهدوء )هياج( أو بشوش ذهنى.<br />- سرعة غير عادية فى دقات القلب أو إنخفاض ضغط الدم.<br />- ألم فى المفاصل او العضلات.<br />- إزرقاق أو نزف بكل سهولة بسبب إنخفاض عدد صفائح الدم.<br />- إنخفاض عدد كريات الدم البيضاء )قلة العدلات(.<br />- صعوبة فى التنفس أو أزيز )تشنج قصبى(.<br />- ضيق نفس )عسر تنفس(.<br />- حكة حادة.<br />أعلم طبيبك فى حال تفاقم أحد التاثيرات التالية أو استمر لأكثر من بضعة أيام:<br />) شائعة )تصيب أقل من شخص واحد من أصل 10<br />- غثيان وإسهال.<br />- زيادة مستوى بعض إنزيمات الكبد فى دمك.<br />) غير شائعة )تصيب أقل من شخص واحد من أصل 100<br />- حكة وطفح جلدى.<br />- فقدان الشهية، اضطراب فى المعدة أو عسر هضم )تخمة(، غثيان )تقيؤ( أو ألم فى منطقة المعدة، شعور بالنفخة )انتفاخ البطن(<br />أو إمساك.<br />- صداع، دوخة، دوار، نعاس, مشاكل فى النوم أو الشعور بالتوتر.<br />- قد تظهر فحوصات الدم نتائج غير عادية بسبب مشاكل فى الكبد أو الكلى.<br />- تغييرات فى عدد كريات الدم البيضاء تظهر فى نتائج بعض فحوصات الدم.<br />- تعب عام.<br />- تغييرات فى عدد بكتريا أخرى أو تتزايد الفطريات مما قد يتطلب العلاج.<br />تأثيرات أخرى:<br />- طفح جلدى حاد قد يتضمن تبثر الجلد او تقشره حول الشفتين والعينين, والفم ,والأنف والأعضاء التناسلية.<br />- فقدان الشهية، إصفرار الجلد والعينين، بول داكن اللون، حكة أو الشعور بألم فى المعدة ) البطن( عند اللمس. قد تكون هذه<br />أعراض مشاكل فى الكبد.<br />تتضمن التأثيرات الجانبية الأخرى:<br />- إنخفاض فى كريات الدم الحمراء )فقر دم(. يمكن أن يسبب هذا شحوب البشرة أو إصفرارها بسبب تضرر كريات الدم الحمراء وإنخفاض عدد كل كريات الدم.<br />- إستجابة مناعية مبالغ فيها )فرط حساسية(.<br />- تعرق كثيف )فرط العرق(.<br />- ألم بما فى ذلك الم الظهر والصدر والأطراف.<br />- مشاكل فى التحرك والسير.<br />- نوبات بريفرية لدى الأشخاص الذين يعانون أصلا من البريفرية )مرض أيضى نادر جدا(.<br />- إلتهاب فى القنوات التى تحمل الدم فى أنحاء جسمك )الأوعية الدموية( بسبب تفاعلات حساسية.<br />فى حال تفاقم أحد هذه التأثيرات الجانبية أو فى حال لاحظت أى تأثيرات غير مذكورة فى هذه النشرة. الرجاء إعلام الطبيب أو<br />الصيدلى</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظه بعيدا عن متناول الأطفال ونظرهم.<br />لاتحفظ الدواء فى درجة حرارة تفوق 30 درجة مئوية.<br />لايتطلب هذا الدواء أى شروط حفظ خاصة ولكن من الأفضل حفظ أقراص ليفوبات 500 فى الظروف والعلبة الأصلية فى مكان<br />جاف.<br />لا تستعمل أقراص ليفوبات 500 بعد إنقضاء تاريخ الصلاحية ( (EXP المدون على علبة الكرتون والرقاقة.<br />يجب عدم التخلص من الأدوية فى المياه المبتذلة أو النفايات المنزلية. إسأل الصيدلى عن كيفية التخلص من الأدوية التى لم تعد بحاجه<br />إليها. فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي الليفوفلوكساسين. يحتوى كل قرص ليفوبات 055 على 055 ملجم من الليفوفلوكساسين.<br />المكونات الأخرى هي:<br />- قلب القرص: نشا، كروسبوفيدون، ، ميكروكريستالين سيليلوز، لاكتوز لامائى و ستيرات الماغنيسيوم.<br />غلاف القرص: هيدروكسى ميثيل بروبيل سيلولوز و أوبادرى أحمر (أو- واى- إس- 35002)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف تبدو أقراص ليفوبات 500 وما هي محتويات العبوة<br />أقراص ليفوبات 500 هى أقراص مغلفة بطبقة خفيفة، بنية محمرة اللون، وللإستعمال عبر الفم.<br />يتوفر الدواء في علبة تحتوي على شريط واحد PVC PVDC/Alu ) يحتوى الشريط على خمسة أقراص مغلفة بطبقة رقيقة<br />ونشرة داخلية مرفقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>بترجي فارما<br />، الشارع رقم: 401، طريق رقم: 403<br />المنطقة الصناعية المرحلة الرابعة،<br />، ص.ب: 10667، جدة 21443<br />المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            April 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEVOBAT 500 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eachfilm coated tablet contain 500 mg of levofloxacin as levofloxacin hemihydrate.
For a full list of excipientssee Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets.
Reddish brown oblong shaped tablets, coded with BP 15 and scored from the same side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEVOBAT 500 is indicated in adults for the treatment of the following infections:<br />&bull; Acute bacterial sinusitis.<br />&bull; Acute exacerbations of chronic bronchitis.<br />&bull; Community-acquired pneumonia.<br />&bull; Complicated skin and soft tissue infections.<br />For the above-mentioned infections LEVOBAT 500 should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.<br />&bull; Pyelonephritis and complicated urinary tract infections.<br />&bull; Chronic bacterial prostatitis .</p><p>&bull; Uncomplicated cystitis.<br />&bull; Inhalation Anthrax: post exposure prophylaxis and curative treatment.<br />LEVOBAT 500 Tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEVOBAT 500 Tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.<br />Posology<br />The following dose recommendations can be given for LEVOBAT 500 Tablets:<br />Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)</p><p>Acute bacterial sinusitis<br />500 mg once daily<br />10 - 14 days</p><p>Acute bacterial exacerbations of chronic<br />bronchitis<br />500 mg once daily<br />7 - 10 days</p><p>Community<br />acquired pneumonia 500 mg once or twice daily<br />7 - 14 days</p><p>Pyelonephritis<br />500 mg once daily<br />7-10 days</p><p>Complicated urinary tract infections<br />500 mg once daily<br />7 - 14 days</p><p>Uncomplicated cystitis<br />250 mg once daily<br />3 days</p><p>Chronic bacterial prostatitis. 500 mg once daily<br />28 days</p><p>Complicated skin and soft tissue infections<br />500 mg once<br />or twice<br />daily<br />7 - 14 days</p><p>Inhalation Anthrax<br />500 mg once daily<br />8 weeks</p><p>&nbsp;</p><p>Special populations<br />Impaired renal function (creatinine clearance &le; 50ml/min)</p><p>Creatinine clearance<br />Dose regimen<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 250 mg / 24 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;500 mg / 24 hrs.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;500 mg / 12 hrs.</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;first dose: 250 mg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; first dose: 500 mg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;first dose: 500 mg</p><p>50-20 ml/min&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; then: 125 mg / 24 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;then: 250 mg/24 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;then: 250 mg/12 h</p><p>19-10 ml/min&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;then: 125 mg / 48 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;then: 125 mg/24 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; then: 125 mg/12 h</p><p>&lt; 10 ml/min (includinghaemodialysis and CAPD)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1 then: 125 mg / 48 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;then: 125 mg/24 h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;then: 125 mg/24 h</p><p>&nbsp;</p><p>1 No additional doses are required after hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).<br />Impaired liver function<br />No adjustment of dose is required since levofloxacin is not metabolized to any relevant extent by the liver and is mainly excreted by the kidneys.<br />Elderly population<br />No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).<br />Pediatric population<br />LEVOBAT 500 Tablets is contraindicated in children and growing adolescents.<br />Method of administration:</p><p><strong>LEVOBAT 500 Tablets should be swallowed without crushing and with sufficient amount of liquid. They may be divided at the score line to adapt the dose. The tablets may be taken during meals or between meals.<br />LEVOBAT 500 Tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminum-containing antacids, or didanosine (only didanosine formulations with aluminum or magnesium containing buffering agents), and sucralfate administration, since reduction of absorption can occur.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin tablets must not be used:
 I n patients hypersensitive to levofloxacin or other quinolones or any of the excipients listed in
section 6.1 6.1.
 I n patients with epilepsy epilepsy.
 I n p atients with history of tendon disorders related to fluoroquinolone administration administration.
 I n children or growing adolescents
 D uring pregnancy and breast feeding.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).<br />Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.<br />Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.</p><p>Inhalation Anthrax: Use in humans is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.<br />Tendinitis and tendon rupture<br />Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance (see section 4.2). Close monitoring of these patients is therefore necessary if they are prescribed levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon (see section 4.3 and 4.8).<br />Clostridium difficile-associated disease<br />Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis(see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is&nbsp;suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.<br />Patients predisposed to seizures<br />Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substance that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.<br />Patients with G-6- phosphate dehydrogenase deficiency<br />Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><p>Patients with renal impairment</p><p>Since levofloxacin is excreted mainly by the kidneys, the dose of levofloxacin should be adjusted in patients with renal impairment (see section 4.2).<br />Hypersensitivity reactions<br />Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.<br />Severe bullous reactions<br />Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with levofloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.<br />Dysglycaemia<br />As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p>Prevention of photosensitisation</p><p>Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.<br />Patients treated with Vitamin K antagonists<br />Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).<br />Psychotic reactions<br />Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour- sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p>QT interval prolongation Caution should be taken when using fluoroquinolones, including levofloxacin in patients with known risk factors for prolongation of the QT interval such as, for example:<br />- congenital long QT syndrome<br />- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).<br />- uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)<br />- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)<br />- Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations.<br />(See sections 4.2 Elderly, 4.5, 4.8 and 4.9).<br />Peripheral neuropathy<br />Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset (see section 4.8). Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.<br />Hepatobiliary disorders</p><p>Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.<br />Exacerbation of myasthenia gravis<br />Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.<br />Vision disorders<br />If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).<br />Superinfection</p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.<br />Interference with laboratory tests<br />In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.<br />Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.<br />Levofloxacin 500mg Film-coated Tablets contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of other medicinal products on LEVOBAT 500 Tablets<br />-Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine:<br />-Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminum-containing antacids, or didanosine (only didanosine formulations with aluminum or magnesium containing buffering agents) are administered concomitantly with LEVOBAT 500 tablets.<br />-Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminum-containing antacids, or didanosine (only didanosine formulations with aluminum or magnesium containing buffering agents) should not be taken 2 hours before or after LEVOBAT 500 tablets administration. Calcium salts have a minimal effect on the oral absorption of levofloxacin.<br />-Sucralfate:<br />The bioavailability of LEVOBAT 500 tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and LEVOBAT 500 tablets, it is best to administer sucralfate 2 hours after the LEVOBAT 500 tablets administration.<br />-Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs<br />No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are&nbsp;given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold.<br />Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.<br />-Probenecid and cimetidine<br />Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.<br />Caution should be exercised when levofloxacin is co-administered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renal impaired patients.<br />-Other relevant information<br />Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin was not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.</p><p>Effect of LEVOBAT 500 tablets on other medicinal products<br />-Cyclosporine<br />The half-life of cyclosporine was increased by 33% when co-administered with levofloxacin.<br />-Vitamin K antagonists<br />Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists.<br />-Drugs known to prolong the QT interval<br />Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics.</p><p>-Other relevant information<br />In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.<br />Other forms of interactions<br />Food<br />There is no clinically relevant interaction with food. LEVOBAT 500 Tablets may therefore be administered regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do<br />not indicate direct or indirect harmful effects with re spect to reproductive toxicity . However in the<br />absence of human data and due to that experimenta l data suggest a risk of damage by fluoroquinolones<br />to the weight bearing cartilage of the growing organism, LEVOBAT 500 tablets mus t not be used in<br />pregnant women<br />Nursing Mothers<br />LEVOBAT 500 tablets are contraindicated in breast feeding women. There is i nsufficient information<br />on the excretion of levofloxacin in human milk; however other fluoroquinolones are excreted in breast<br />milk. In the absence of human data and due to that experimental data suggest a risk of damage by<br />fluoroquinolones to the weight be aring cartilage of the growing organism, levofloxacin must not be<br />used in breast feeding women<br />Fertility<br />Levofloxacin caused no impairment of fertility or reproductive performance in rats.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable<br />effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the<br />patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these<br />abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.<br />Frequencies are defined using the following convention: very common (&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10000, &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness</p><p>Infections and infestations<br />Uncommon: Fungal infection<br />Including Candida<br />Pathogen, resistance</p><p>Blood and lymphatic system disorders</p><p>Uncommon: Leukopenia,<br />Eosinophilia<br />Rare: Thrombocytopenia Neutropenia<br />Not known: Pancytopenia, Agranulocytosis, Hemolytic anemia</p><p>Immune system disorders<br />Rare:Angioedema Hypersensitivity<br />Not known: Anaphylactic shock</p><p>Metabolism and nutrition disorders<br />Rare:Anorexia<br />Hypoglycemia<br />Not known:particularly in diabetic patients<br />Hyperglycemia<br />Hypoglycemic coma</p><p>Psychiatric disorders<br />Common: Insomnia<br />Uncommon: Anxiety<br />Confusional state<br />Nervousness<br />Rare: Psychotic reactions (with e.g. hallucination, paranoia) Depression Agitation Abnormal dreams Nightmares<br />Not known: Psychotic&nbsp;disorders with self endangering<br />behaviour includingsuicidal ideation or suicide attempt</p><p>Nervous system disorders<br />common: Headache<br />Dizziness<br />uncommon: Somnolence<br />Tremor<br />Dysgeusia<br />Rare: Convulsion, Paraesthesia<br />Not known: Peripheral sensory neuropathy, Peripheral sensory motor, neuropathy, Parosmia including anosmia, Dyskinesia, Extrapyramidal disorder<br />Ageusia , Syncope Benign intracranial hypertension</p><p>Eye disorders<br />Rare: Blurred vision<br />not known: Transient vision loss</p><p>Ear and Labyrinth disorders<br />uncommon:Vertigo<br />rare:Tinnitus<br />not known: Hearing loss<br />Hearing impaired</p><p>Cardiac disorders<br />rare: Tachycardia,<br />Palpitation<br />not known: Ventricular tachycardia,<br />which may result in<br />cardiac arrest Ventricular<br />arrhythmia and torsade<br />de pointes (reported<br />predominantly in patients<br />with risk factors of QT<br />prolongation),<br />Electrocardiogram QT<br />prolonged</p><p>Vascular disorders<br />rare: Hypotension</p><p>Respiratory, thoracic and mediastinal<br />disorders<br />uncommon: Dyspnea<br />not known: Bronchospasm,<br />Pneumonitis allergic</p><p>astrointestinal disorders<br />common: Diarrhea<br />Vomiting<br />Nausea<br />uncommon:Abdominal pain<br />Dyspepsia<br />Flatulence<br />Constipation<br />not known: Diarrhea &ndash;hemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudomembranous colitis and Pancreatitis</p><p>Hepato-biliary disorders<br />common:Hepatic enzyme increased (ALT/AST, alkaline, phosphatase, GGT)<br />uncommon:Blood bilirubin increased<br />rare:Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily in patients with severe underlying diseases Hepatitis</p><p>Skin and subcutaneous tissue disordersb<br />uncommon:Rash<br />Pruritus<br />Urticaria<br />Hyperhidrosis</p><p>rare:Toxic epidermal necrolysis<br />Stevens-Johnson syndrome<br />Erythema multiform<br />Photosensitivity reaction<br />Leukocytoclastic vasculitis , Stomatitis</p><p>Musculoskeletal and connective tissue disorders<br />uncommon:Arthralgia<br />Myalgia<br />rare:Tendon disorder including tendinitis (e.g. Achilles tendon)<br />Muscular weakness which may be of importance in patients with myasthenia gravis<br />not known:Rhabdomyolysis<br />Tendon rupture (e.g. Achilles tendon), Ligament rupture<br />Muscle rupture<br />Arthritis</p><p>Renal and urinary disorders<br />uncommon:Blood creatinine<br />rare: increased Renal failure acute (e.g. due to intersti tial nephritis)</p><p>General disorders and administration site conditions<br />uncommon: Asthenia<br />rare: Pyrexia<br />not known: Pain (including pain in<br />back, chest, and<br />extremities)</p><p>&nbsp;</p><p>b Mucocutaneous reactions may sometimes occur even after the first dose<br />Other undesirable effects which have been associated with fluoroquinolone administration include:<br /> Attacks of porphyria in patients with porphyria.<br />-<br />To report any side effect(s) in Saudi Arabia;<br />-<br />National Pharmacovigilance Center (NPC)<br /> Fax: +966 11 205 7662<br /> Toll free number: 8002490000 / 19999<br /> E mail: npc.drug@sfda.gov.sa<br /> Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of LEVOBAT 500 tablets are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.<br />CNS effects including confusion, convulsion, hallucination, and tremor have been observed in post marketing experience.<br />In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Hemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones</p><p>ATC code:<br />J01MA12<br />Levofloxacin is a synthetic antibacterial agent of th<br />e fluoroquinolone class and is the S ( (--) enantiomer<br />of the racemic active substance ofloxacin.<br />Mechanism of action<br />As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.<br />PK/PD relationship<br />The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).<br />Mechanism of resistance<br />Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may also affect susceptibility to levofloxacin.<br />Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism&nbsp;of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 - 2 h. The absolute bioavailability is 99 - 100 %.<br />Food has little effect on the absorption of levofloxacin.<br />Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.</p><p>Distribution<br />Approximately 30 - 40 % of levofloxacin is bound to serum protein.<br />The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.<br />Penetration into tissues and body fluids<br />Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.<br />Biotransformation<br />Levofloxacin is metabolized to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for &lt; 5 % of the dose excreted in urine. Levofloxacin is stereo chemically stable and does not undergo chiral inversion.<br />Elimination<br />Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from&nbsp;the plasma (t&frac12; : 6 - 8 h). Excretion is primarily by the renal route (&gt; 85 % of the administered dose).<br />The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/-29.2 ml/min.<br />There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.<br />Linearity<br />Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.<br />Special populations<br />Subjects with renal insufficiency</p><p>The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function, renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:<br />Pharmacokinetics in renal insufficiency following single oral 500 mg dose<br />Cl&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; cr [ml/ &lt; 20&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 20-49&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;50-80</p><p>ClR [ml/min&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;13&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;26&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 57</p><p>t1/2 [ h&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;35&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 27&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 9</p><p>&nbsp;</p><p>Elderly subjects<br />There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.<br />Gender differences<br />Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.<br />Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.<br />Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photo mutagenicity assay, and it reduced tumor development in a photo carcinogenetic study.<br />In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br /> Pregelatinised Starch.<br /> Crospovidone.<br /> Microcrystalline cellulose.<br /> Lactose anhydrous DC.<br /> Magnesium stearate.<br />Tablet coat:<br /> Hydoxypropyl methylcellulose.(HPMC 15 cp)<br /> Opadry red OY-S-35002.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24
months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carton box containing one PVC /PVDC Aluminium blister (of 5 coated tablets ) and a</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BATTERJEE PHARMA
Street No.: 401, Road No.: 403,
Industrial Area
Phase IV,
P.O. Box: 10667, Jeddah
21443,
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>